Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT-2 inhibitors and cardiovascular autonomic neuropathy in type 2 diabetes
2025-521748-39-00Phase 4Completed
- Sponsor
- Università Cattolica del Sacro Cuore
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of empagliflozin, canagliflozin, ertugliflozin and dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Università Cattolica del Sacro Cuore. Primary endpoints: Change in LF:HF ratio and Improvement in cardiovascular autonomic neuropathy progression and glucose variability. Started Nov 2025; status: completed.
02
Drugs
empagliflozincanagliflozinertugliflozindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-521748-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521748-39-00.